12 December 2023
12 December 2023
The Clinical Trials Arena team also reviews assets in oncology, metabolic disorders and musculoskeletal disorders.
Merck (MSD) and Moderna are also conducting a Phase III trial evaluating the combination therapy in patients with resected high-risk melanoma.
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for odronextamab in diffuse large B-cell lymphoma and follicular lymphoma on 31 March 2024.
The company intends to begin the trial in the second half of next year.
Vueway has halve the dose of gadolinium compared to standard agents but has shown greater enhancement of contrast in clinical trials.
The trial subjects will be treated with GLM101 for 24 weeks.
Swedish company Verigraft is personalising vein transplants to remove the need for immune-suppressive agents.
The trial is intended to analyse the tolerability and safety of ATG-031 as a single agent.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
